My ePortfolio Register   

How does our understanding of signaling pathways inform treatment decisions in CLL and FL?

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
This content is restricted to members who are registered with ecancer as a healthcare professional
Please login or register for free to confirm your details.
Published: 18.08.17
Views: 750

Prof Paolo Ghia - San Raffaele Scientic Institute, Milan, Italy

Prof Paolo Ghia speaks at the 'Defining treatment strategies for CLL & FL in the era of targeted therapies' symposium at EHA 2017 about the mechanisms of action and associated adverse effect profiles for idelalisib, ibrutinib and venetoclax.

Click here for prescribing information


Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence